WHO ICTRP trial
A double-blind Phase I study to investigate safety, tolerability, and…
ACTRN12616001437459 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12616001437459 |
|---|---|
| Public title | A double-blind Phase I study to investigate safety, tolerability, and pharmacokinetics of single and repeated escalating doses of EU-C-001 given as intravenous infusions and as oral administrations in healthy male subjects |
| Scientific title | A double-blind Phase I study to investigate safety, tolerability, and pharmacokinetics of single and repeated escalating doses of the NK1 receptor antagonist EU-C-001 given as intravenous infusions and as oral administrations in healthy male subjects |
| Primary sponsor | PresSura Neuro Ltd |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Traumatic brain injury; Traumatic brain injury;Neurological - Other neurological disorders |
| Interventions | EU-C-001: Group 1: Single oral administration (5mg, 15mg, 45mg, 90mg, 150mg, 180mg) Each subject will receive one single oral administration of the study medication, either EU-C-001 or placebo. At each dose levels, six male subjects will… |
| Registration date | Oct 14, 2016 |
| Target size | 114 |
| Secondary IDs | Nil known |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: